Biography

Dr. Daniel Acosta

Medical Oncology

Spain

13 years of experience

Specialty

Specialties:

Medical Oncology

Subspecialties:

Pancreas tumors, Biliary tract tumors, Liver tumors, Esophageal tumors, Gastric tumors, Colon tumors, Neuroendocrine tumors

Procedures performed:

Chemotherapy, Immunotherapy, Targeted therapies, Drug development/Clinical research

Work Experience

Medical Oncologist

Vall d’Hebron University Hospital

Barcelona, Spain.

from 2019

Medical Oncologist

GenesisCare

Madrid, Spain.

2016 - 2019

Medical Oncologist

Comprehensive Cancer Center CLARA CAMPAL

Madrid, Spain.

2014 - 2016

Medical Oncology Residency Program

San Carlos Clinical Hospital

Madrid, Spain.

2009 - 2014

Biography

Dr. Acosta is a medical oncologist and a clinical researcher in the Digestive and Endocrine Tumors Unit of Vall d´Hebron Institute of Oncology (VHIO). He takes part in various national and international organizations dedicated to his specialty (Spanish Society of Medical Oncology, European Society for Medical Oncology, American Society of Clinical Oncology, The European Neuroendocrine Tumor Society, and Spanish Group of Neuroendocrine and Endocrine Tumors).

Dr. Acosta's main specialty is in Digestive Tumors and he is also skilled in the treatment of Pancreas, biliary tract, liver, esophageal, gastric, colon, and neuroendocrine tumors. Dr. Acosta performs chemotherapy, immunotherapy, and target therapies as a specialist in oncology. He is also experienced in drug development (clinical research).

Education

MD, University of San Martin de Porres

2008

Awards

No data found

Affiliations

Spanish Society of Medical Oncology

European Society for Medical Oncology

American Society of Clinical Oncology

The European Neuroendocrine Tumor Society

Spanish Group of Neuroendocrine and Endocrine Tumors

Publications

Experience with eribulin in patients with metastatic breast cancer and associated hepatic impairment: Case studies

Identification of E545k mutation in plasma from a PIK3CA wild-type metastatic breast cancer patient by array-based digital PCR. cfDNA a powerful tool for biomarker testing in advance disease

Tumor burden monitoring using cell-free tumor DNA could be limited by tumor heterogeneity in advanced breast cancer and should be evaluated together with radiographic imaging